BackNanoVibronix Overview

NanoVibronix Current Cash

Track NanoVibronix's current cash ($2.2M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$2.23M
↑ 271.88% YoYΔ $1.63M vs prior year quarter

Peer average / median

Loading

NanoVibronix Current Cash History

Loading

NanoVibronix vs. peers: Current Cash Comparison

Loading

NanoVibronix Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

NanoVibronix (NAOV) FAQ

NanoVibronix (NAOV) currently reports a current cash of $2.2M as of March 2026. That compares with $600K in the prior-year period — up 271.9% year over year. Use the charts on this page to explore NanoVibronix's current cash history and peer comparisons.

NanoVibronix's current cash increased from $600K to $2.2M — a 271.9% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

NanoVibronix reported $2.2M in current cash as of March 2026. That compares with $600K in the prior-year period — up 271.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $2.2M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for NanoVibronix, and consider following NAOV for alerts when major investors trade the stock.

NanoVibronix is classified in the Healthcare sector. On current cash, it currently shows $2.2M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NAOV with unrelated industries.